"CTI Business Strategy for Cancer Research, Cancer Therapies, and Cancer Drug Development"
Our goal is to build a leading, vertically integrated biopharmaceutical
company with a diversified portfolio of proprietary
cancer drugs.
The following are the key elements of our business strategy:
We target development and registration strategies in
the United States or Europe that take advantage of
the ability to accelerate approval either because there
is an unmet medical need, or because our product profiles
demonstrate significant
improvement in efficacy or safety
over competitive cancer drugs.
We plan to devote a substantial portion of our efforts
to develop XYOTAX and
pixantrone.
We have development capabilities to expand our portfolio of improved
versions of currently marketed anti-cancer drugs. In addition,
we are actively researching more novel drug targets
that will deliver agents with improved side effect
and efficacy profiles compared to competitor cancer
drugs.